pericyte component, inhibited neovascularization and growth of uveal melanoma xenografts. For this, we used multichannel laser scanning confocal microscopy and quantitative image analysis.
Introduction
The walls of neovascular capillaries are composed of two principal cell types: vascular endothelial cells and pericytes (Rouget cells). In this investigation, we explored whether knockout of nerve/glial antigen 2 (NG2), a bodies against the NG2 proteoglycan [2] . Rabbit polyclonal glial fibrillary acidic protein (Accurate Chemical, Westbury, N.Y., USA) and PDGF ␣ -receptor antibodies (a kind gift from Dr. William B. Stallcup) were used to identify glia. Slides incubated with nonspecific immunoglobulin served as a negative control.
The immunostained sections (3 sections per eye from 18 eyes) were analyzed with an Olympus Fluoview 1000 multi-channel laser scanning confocal microscope for microvascular density (MVD). The Volocity image analysis software (Openlab-Improvision Inc, Lexington, Mass., USA) was used for quantification of MVD in pixels in sections immunostained with endoglin (CD105), PECAM-1 (CD31) and VEGF receptor-2 (flk-1). The average equatorial radius (R) of each tumor in hematoxylin and eosinstained histological slides was measured by using the Volocity image analysis software. Then the volume of each tumor was estimated using the formula 4/3 ! ! R 3 .
Results
On dilated indirect ophthalmoscopic examination, the tumor mass was identified at the peripheral fundus. The visual axis was intact, and the anterior chamber, cornea, lens, and vitreous were clear ( fig. 1 a) . Both NG2 knockout ( fig. 1 b) and wild-type ( fig. 1 c) eyes developed tumors in uvea.
Immunostaining for NG2 and PDGF ␤ -receptors revealed NG2-negative and PDGF ␤ -receptor-positive pericytes in NG2 knockout mice and NG2-positive and PDGF ␤ -receptor-positive pericytes in the wild-type mice. PDGF ␤ -receptor and [endoglin (CD105), PECAM-1 (CD31), and VEGF receptor-2 (flk-1)] double immunostaining revealed investment of endothelium with pericytes ( fig. 1 d, 
Discussion
The use of the xenograft model and cyclosporin administration for immunosuppression may somewhat confound the interpretation of the results in the context of tumor-host interactions and neovascular cell recruitment. The cyclosporin inhibits angiogenesis by inhibiting migration of vascular precursors. This effect is mediated through the inhibition of cyclooxygenase 2, the transcription of which is modulated by the nuclear factor of activated T cells [3] . Therefore, immunosuppression of the mice in order to prevent rejection of the human tumor xenograft, although necessary, presents a significant problem. However, four observations presented in our study seem especially noteworthy.
First, pericytes contribute to the neovascular vessels of uveal melanoma extensively. To our knowledge, there are at least two reports on the presence of ␣ -smooth muscle actin-positive pericytes in uveal melanoma [4, 5] . Since only a small fraction (1-10%) of nascent pericytes can be identified on the basis of ASMA expression [6] , we used NG2 and PDGF ␤ -receptor immunohistochemistry to identify pericytes.
The current investigation represents the first report on therapeutic targeting of pericytes in uveal melanoma. Presence of NG2-negative and PDGF ␤ -receptor-positive pericytes in uveal melanoma in NG2 knockout mice also suggests that neovascular pericytes in uveal melanoma derive from the host tissue, but not from the grafted tumor.
Second, genetic inhibition of pericyte-NG2 proteoglycan decreases MVD in uveal melanoma. NG2, a membrane-spanning chondroitin sulfate proteoglycan associated with mitotically active, nascent pericytes exhibits several properties, which suggests that it is a functional player in neovascularization [7, 8] . NG2 appears to serve as a coreceptor for bFGF (basic fibroblast growth factor) [9] . Recent investigations have revealed decreased neovascularization following intrinsic or extrinsic targeting of NG2 proteoglycan in retinal ischemia, neurofibromatosis type 1, in bFGF-induced neovascularization in cornea.
Third, the reduction of the MVD leads to a significant inhibition of uveal melanoma growth. These results sug- MVD was quantified in pixels using Volocity image analysis software on 54 frozen sections which were sampled from 18 eyes, and immunostained for endoglin (CD105), PECAM-1 (CD31), and VEGF receptor-2 (flk-1). a MVD in NG2 knockout eyes was 43.7% lower than in wild-type controls, and this difference was statistically significant (n = 18 eyes, p = 0.0166, MannWhitney U test). b MVD in uveal melanoma in a knockout eye. Scale bar indicates 75 m. c Tumor in a control eye (wild-type). Scale bar indicates 75 m.
gest a 95% reduction of the tumor end volume at the time of sacrifice in NG2 knockout mice. Fourth, expression of NG2 proteoglycan on both pericytes and uveal melanoma cells renders this proteoglycan a double target.
The current study expands our understanding of the neovascularization process in uveal melanoma xenografts and establishes a role for pericytes and NG2 proteoglycan as potential therapeutic targets.
